US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...
The NHS will deny 90 per cent of eligible obese patients the “King Kong” of weight loss jabs, citing budget pressures. The ...
Mounjaro will be made available on the NHS but the rollout will be phased, with only those with the highest need getting the ...
Emmanuel Macron is facing calls to resign the presidency over the collapse of France's government, reports the Times. The ...
Brooks admitted that when she was taking Ozempic she 'lost a little bit of the motivation and the strength to work out.' ...
Mounjaro will be rolled out gradually as officials said a "difficult decision" had to be made in order to "protect other ...
A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.